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Abstract
More than a decade has passed since apolipoprotein E4 (APOE-ε4) was identified as a primary risk
factor for Alzheimer 's disease (AD), yet researchers are even now struggling to understand how
the apolipoprotein system integrates into the puzzle of AD etiology. The specific pathological
actions of apoE4, methods of modulating apolipoprotein E4-associated risk, and possible roles of
apoE in normal synaptic function are still being debated. These critical questions will never be fully
answered without a complete understanding of the life cycle of the apolipoprotein receptors that
mediate the uptake, signaling, and degradation of apoE. The present review will focus on apoE
receptors as modulators of apoE actions and, in particular, explore the functions of soluble apoE
receptors, a field almost entirely overlooked until now.
Background
ApoE and apoE receptors
Apolipoprotein E (apoE) is a small (34-kDa) secreted
glycoprotein that associates with lipoproteins and medi-
ates uptake of these particles into target cells via receptor-
mediated endocytosis by the low density lipoprotein
(LDL) receptor family. Three commonly occurring iso-
forms have been identified in the human population due
to single nucleotide polymorphisms on the APOE gene on
chromosome 19. The apoE3 isoform (Cys112, Arg158)
occurs at the highest frequency, followed by apoE4
(Arg112, Arg158) and apoE2 (Cys112, Cys158). ApoE is a
ligand for the seven identified mammalian members of
the evolutionarily conserved low density lipoprotein
(LDL) receptor family: the low density lipoprotein recep-
tor (LDLR), apoE receptor 2 (ApoER2), the very low den-
sity lipoprotein receptor (VLDLR), multiple epidermal
growth factor (EGF) repeat-containing protein (MEGF7),
megalin, LDL-related protein-1 (LRP1) and LDL-related
protein-1b (LRP1b). APOE was initially recognized for its
importance in lipoprotein metabolism and cardiovascular
disease, however, more recently it has been studied for its
role in several biological processes not directly related to
lipoprotein transport. The following review will focus on
the role of apoE and apoE receptors in the CNS with a
focus on the processing and production of soluble apoE
receptors.
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Genetics of apoE and Alzheimer's disease
Alzheimer's disease (AD) is a complex neurodegenerative
condition characterized neuropathologically by the pres-
ence of extracellular amyloid plaques, intraneuronal neu-
rofibrillary tangles, and neuronal loss. While most AD is
sporadic in nature, two classes of genetic risk factors for
AD have been identified. The first class consists of muta-
tions responsible for the rare, familial AD (FAD). Genes
implicated in FAD include the β-amyloid protein precur-
sor (APP), presenilin-1, and presenilin-2; mutations in
these genes produce AD risk marked by autosomal domi-
nance, early disease onset, high penetrance, and relative
rarity, on the order of hundreds of families worldwide
(reviewed in [1]). Each of the mutated forms of these
genes enhances the production of amyloid-β (Aβ) peptide
[2], particularly the 42 amino acid form (Aβ42). Because
Aβ42 aggregates to form amyloid, the discovery of these
genes strongly supports the "amyloid hypothesis" [2].
A second class of AD risk factor is genetic variation that
modulates the sporadic late onset AD; at present, the sole
member of this class is the APOE gene. APOE encodes a
secreted protein of 299 amino acids important for the
transport of cholesterol. Single nucleotide polymor-
phisms (SNP) define three common alleles (ε2, ε3, and
ε4), which encode proteins that differ at two amino acids.
APOE-ε2  is associated with reduced odds and delayed
onset of AD while APOE-ε4 is associated with increased
odds and earlier onset of AD [3]. APOE-ε4  appears to
account for up to 40–50% of the genetic risk of AD [4,5].
Furthermore, APOE-ε4 is associated with increased brain
Aβ in affected individuals [6]. The effects of APOE on Aβ
burden are seen in mice as well, with studies in mice defi-
cient for apoE or transgenic for human apoE supporting a
role for apoE in Aβ fibrillogenesis and neuritic plaque for-
mation [7,8]. Importantly, the risk associated with APOE-
ε4 is modulated by other unknown genetic and environ-
mental factors.
AD has a complex etiology that encompasses environ-
mental factors as well as the genetic risk factors. The exist-
ence of environmental risk factors is demonstrated by
multiple lines of evidence, including studies of twins.
Interestingly, it was found that only about half of identical
twins have concordance for AD [9,10]. Among the envi-
ronmental factors identified, cholesterol lowering treat-
ments (reviewed in [11,12]) and anti-inflammatory drugs
(reviewed in [13]) may decrease risk of AD. Alternatively,
analysis of post-mortem AD brains showed an increased
level of traumatic brain injury compared to normal non-
AD brains, suggesting that brain trauma may significantly
increase the risk of AD [14]. ApoE is potentially involved
in each of these environmental factors.
ApoE and apoE receptors in the CNS
ApoE and cholesterol transport in the CNS
In the periphery, there are numerous lipoprotein classes
and apolipoproteins. However, in the CNS, lipoproteins
are predominantly high density and do not include the
large classes of lower density lipoproteins found in the
plasma [15]. The two major apolipoproteins present in
the cerebral spinal fluid (CSF) are apoE and apoAI; classes
of high density lipoproteins in the CSF contain either or
both of these apolipoproteins [16]. These lipoproteins
can act either to deliver cholesterol to cells, or to remove
excess cholesterol from cells [17]. The additional role of
these proteins as signaling molecules will be discussed
later in this review.
ApoE and Aβ
The strongest associations of APOE genotype with disease
are with conditions containing amyloid deposition
including AD, Down's syndrome, cerebral amyloid angio-
pathy and head trauma [6,18-23]. In vivo, early evidence
for an involvement of apoE in AD came from immunohis-
tochemical localization of apoE to senile plaques [24].
ApoE4 increases levels of amyloid deposition in humans
[6,18] and accelerates amyloid deposition in transgenic
mice [8,25,26]. Recent research has focused on soluble
oligomeric assemblies of Aβ as the proximate cause of
neuronal injury, synaptic loss and the eventual dementia
associated with AD [27-31]. ApoE binds soluble Aβ oli-
gomers found in the brain, plasma and CSF [32,33]. In
vitro, apoE forms stable complexes with Aβ [34-37], alters
the aggregation of various Aβ peptides [38-40], modulates
Aβ-induced neuroinflammation [41-44], and promotes
Aβ clearance [45]. In addition, Aβ42 and apoE4 act syner-
gistically to reduce neuronal viability in vitro and ex vivo
as measured by neurotoxicity in primary cultures and
impaired long term potentiation (LTP) in hippocampal
slice cultures [46-51]. Each of these important functions is
partially mediated by apoE receptors.
ApoE receptors
ApoE interacts with members of the LDL receptor family
on the surface of cells. The LDLR family consists of over
ten receptors that function in receptor-mediated endocy-
tosis and cellular signaling (Figure 1) [52,53]. In addition
to the LDLR itself, the family includes LRP/LRP1 [54],
megalin/LRP2 [55], VLDLR [56], ApoER2/LRP8 [57-59],
SORLA-1/LR11 [60,61], LRP4 [62], LRP5 [63,64], LRP6
[65], and LRP1B [66]. The most characteristic structural
component of the LDLR family is the cysteine-rich ligand-
binding repeats forming ligand-binding domains [52,67].
Additionally, most members of the LDLR family contain
epidermal growth factor (EGF)-like repeats and YWTD
motifs, which form β-propeller-like structures [68]. A
common feature that is shared by most members of the
LDLR family is their ability to bind the receptor-associatedMolecular Neurodegeneration 2006, 1:15 http://www.molecularneurodegeneration.com/content/1/1/15
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protein (RAP) [69]. RAP is an endoplasmic reticulum
(ER)-resident protein that functions in receptor folding
and trafficking along the early secretory pathway and uni-
versally antagonizes ligand-binding to all members of the
family [69].
Many of the apoE receptors have been found in the CNS.
Neurons express LDLR, LRP, ApoER2, and the VLDLR;
astrocytes express LDLR and LRP; microglia express
VLDLR and LRP [6,57,70-73]. It is unclear which receptors
are expressed on oligodendrocytes. Soluble forms of each
of these receptors have been detected (see below).
ApoE receptors and endocytosis
A major function of at least some of the apoE receptors is
clathrin-mediated endocytosis. The rapid endocytosis rate
of LRP is unique among LDLR family members. The dom-
inant endocytosis signal for LRP is the YXXL motif [74].
The two copies of the NPXY motif, which mediates LDLR
endocytosis [75], do not play significant roles in LRP
endocytosis but likely bridge interactions with adaptor
proteins for signaling and intracellular trafficking. The ini-
tial endocytosis rates of individual LDLR family members
are significantly different with half time for internaliza-
tion ranging from <0.5 min (LRP) to > 8 min (ApoER2/
VLDLR) ([76], see Table 1). These results suggest endo-
cytic functions among LDLR family members are distinct.
In addition to endocytosis, LDLR family members also
exhibit efficient recycling. In particular, sorting nexin 17,
a member of the PX-domain containing, sorting nexin
family, interacts with the proximal NPXY motif of the LRP
tail and promotes its recycling in the early endosome [77].
Other adaptor proteins, specifically Dab-1 and FE65,
affect levels of surface apoE receptors [78]. Although sig-
nificant cholesterol from the periphery does not get trans-
ported into the CNS and sufficient cholesterol is
synthesized in the CNS [79], cholesterol redistribution is
important for transport of cholesterol from glia to neu-
rons [80] and for clearance of membrane debris after CNS
damages [81].
ApoE receptors and intracellular signaling
Recently, several studies have demonstrated a role for
some apoE receptors (specifically LRP, ApoER2, and
VLDLR) as signaling molecules (see [53,82] for review).
VLDLR and ApoER2 transduce signals from the extracellu-
lar matrix molecule Reelin, affecting neuronal cell migra-
tion during development [83]. LRP activation by ligand
binding affects NMDA receptor function [84-89]. These
effects are transduced through the cytoplasmic domains
of receptors binding various cytoplasmic adaptor and
scaffold proteins containing PID or PDZ domains, includ-
ing mammalian Disabled-1 (mDab1), mDab2, FE65,
JNK-interacting protein JIP-1 and JIP-2, and PSD-95 [90-
95]. ApoE receptor ligands also promote other intraneuro-
nal signals via apoE receptors, including PI3 activation,
ERK activation, and JNK inhibition [86,96,97] but exactly
which receptors promote which signals is unknown. ApoE
receptors on glia also affect signaling pathways, affecting
the state of glial activation [41,42,98].
ApoE receptors and synaptic plasticity
These receptor-mediated processes defined in vitro are
important for brain physiological functions. The apoE
receptor antagonist RAP prevents induction of long-term
potentiation (LTP) in hippocampal slices [69]. ApoER2
and VLDLR knock-out (KO) mice have normal baseline
synaptic transmission, as measured in acute hippocampal
slices, but have subtle impairment of hippocampal LTP
[83,99]. Moreover, Reelin application enhanced LTP
induction, which was dependent on the presence of both
ApoER2 and VLDLR [97]. A potential molecular mecha-
nism for this function of ApoER2 is a 59 amino acid cyto-
plasmic domain that is alternatively spliced. This ApoER2
splice variant interacts with PSD-95, which is itself associ-
ated with NMDA receptor conductance [87,95]. Knock-in
mice exclusively expressing ApoER2 receptors that lack the
59 amino acid insert exhibit decreased LTP induction, and
no enhancement of LTP in the presence of exogenous Ree-
lin [87]. Thus, the role of ApoER2 in LTP appears to be in
the capacity of NMDA receptor modulation by increasing
LDL receptor family members Figure 1
LDL receptor family members. LDLR, ApoER2, VLDLR 
and LRP represent the four major apoE receptor family 
members in the mammalian CNS. Each member contains a 
single transmembrane domain, at least one ligand binding 
domain, EGF repeat, YWTD β-propeller and cytoplasmic 
NPxY motif.Molecular Neurodegeneration 2006, 1:15 http://www.molecularneurodegeneration.com/content/1/1/15
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NMDAR conductance and thus indirectly altering intracel-
lular calcium levels.
ApoE isoforms and synaptic plasticity
Increasing evidence indicates that apoE4 itself impairs
neuronal viability. Not all cell types are susceptible to
apoE4-induced toxicity; glia are relatively resistant [100]
and only cells with a neuronal phenotype appear vulner-
able [101]. ApoE4 actually inhibits neurite outgrowth,
overrides the neurite-stimulatory effect of apoE3 and is
neurotoxic in vitro (reviewed by Teter [102]). Transgenic
expression of human apoE4 has dominant negative
behavioral effects [103-106], including deficits in mem-
ory tasks [103,105]. In addition, apoE4 mice a exhibit
greater memory impairment than apoE-knockout (apoE-
KO) mice, suggesting that apoE4 confers a gain of negative
function [106,107].
Several studies utilizing genetically altered mice have
begun to shed light on the roles of apoE in synaptic plas-
ticity and memory formation. ApoE targeted replacement
mice (apoE-TR mice) express one of the three human iso-
forms under the control of endogenous murine APOE
promoter sequences in a conformation and at physiolog-
ical levels in a temporal and spatial pattern comparable to
endogenous mouse apoE [108]. ApoE-TR mice expressing
the apoE3 isoform are identical to wild type mice in both
LTP induction and spatial learning. In contrast, mice
expressing the apoE4 isoform demonstrate compromised
LTP induction and spatial learning. Importantly, the
impaired spatial learning exhibited by apoE-deficient
mice can be rescued by infusion of human apoE3 or
apoE4 [109,110]. Thus, apoE and its receptors influence
NMDA receptor activity, LTP, and spatial memory.
ApoE, Aβ, and synaptic plasticity
In addressing the effect of apoE on Aβ-induced changes in
neuronal viability, it is unclear precisely what form of the
Aβ peptide was used in early studies because it has been
difficult to isolate and determine the conformational spe-
cies of Aβ responsible for its neural activity [50,51]. In
vitro, several recent studies have demonstrated that apoE2
and E3, but not E4, protect neurons against cell death
induced by non-fibrillar Aβ, but have no effect on fibril-
lar-induced toxicity [111,112]. In addition, oligomeric
Aβ42-induced neurotoxicity is significantly greater in
both Neuro-2A cells treated with apoE4 [112-114] and
primary co-cultures of wild-type (WT) neurons and glia
from apoE-TR mice expressing apoE4 [47,112]. Using
apoE-TR mice, oligomeric Aβ42-induced inhibition of
LTP was greatest in hippocampal slice cultures from
apoE4-TR mice, while apoE2 actually protected against
LTP impairment [46]. In vivo, crossing apoE2 transgenic
mice with APP transgenic mice prevented soluble Aβ-
induced dendritic spine loss [115].
Summary
Of the two major apolipoproteins found in the CSF, apoE
can associate to a number of extracellular molecules and
bind to four major CNS apoE receptors; VLDLR, ApoER2,
LDLR and LRP. The apoE4 isoform has garnered attention
due to the genetic association of apoE4 inheritance and
AD risk. ApoE receptors undergo rapid clathrin-mediated
endocytosis following ligand binding and have the ability
to link ligand binding to several signal transduction path-
ways. ApoE isoforms exhibit a differential affect on synap-
tic function and VLDLR and ApoER2 are shown to play a
role in synaptic plasticity and memory formation.
ApoE receptors and AD
ApoE receptors are an integral part of normal apoE metab-
olism, potentially mediating and/or modulating the
effects of apoE isoforms on AD pathological processes.
They are also important for the cellular homeostasis of
cholesterol, which may also affect Aβ production from
APP [12]. Several lines of research have implicated apoE
receptors directly in AD pathophysiology through several
mechanisms (Figure 2).
ApoE receptors endocytose Aβ
Almost from the initial observations that apoE bound Aβ
[24,34], apoE receptors have been suggested to act as
clearance mechanisms for Aβ. Since then, apoE receptors
have been found to help transport Aβ across the endothe-
lial cells forming the blood brain barrier [116] or clear Aβ
into astrocytes as a degradative process [45]. ApoE is
found on most, but not all Aβ deposits in the AD brain
[117,118]. LRP is expressed on activated astrocytes [6] and
closely associated with Aβ deposits [119]. The importance
of Aβ clearance via apoE receptors is also supported by the
significant increase in amyloid deposition observed in
transgenic APP mice deficient in the RAP gene [120],
Table 1: ApoE receptor endocytosis rates.
Receptor t1/2
LRP 0.5 min
LDLR 4.8 min
ApoER2 8.1 min
VLDLR 8.2 minMolecular Neurodegeneration 2006, 1:15 http://www.molecularneurodegeneration.com/content/1/1/15
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which has increased levels of several LDLR family mem-
bers [121,122]. Thus, the interactions of apoE complexes
with the apoE receptors in the CNS vitally affect not only
the metabolism of apoE, but of Aβ as well.
LRP alters APP trafficking and processing
ApoE receptors also have been implicated in the produc-
tion of Aβ. LRP interacts with APP through the intracellu-
lar adaptor protein FE65 or via direct binding to the KPI
domain [90,123-126]. Functionally, LRP's rapid endocy-
tosis facilitates APP endocytic trafficking and Aβ produc-
tion [127-129]. Overexpression of a functional LRP
minireceptor in vivo resulted in an increase of soluble Aβ
in the brain [130].
Other members of the LDLR family alter APP trafficking and 
processing
The apoE receptor LRP1B, which undergoes a slow endo-
cytosis, interacts with APP. However, unlike LRP, expres-
sion of LRP1B decreases APP endocytic trafficking and
processing to Aβ [131]. ApoER2 also interacts with APP,
through an extracellular matrix molecule F-spondin [132]
and the intracellular adaptor protein FE65 [78]. These
studies suggest that conditions that stabilize APP on the
cell surface can increase α-cleavage of APP and decrease
Aβ production. Finally, several recent studies have shown
that SorLA/LR11 alters APP trafficking to discrete com-
partments such that APP processing by β/γ-secretases is
decreased [133-136]. Together these studies indicate that
ApoE receptors and AD pathophysiology Figure 2
ApoE receptors and AD pathophysiology. ApoER2 and LRP receptors can mediate several intracellular signaling kinases 
including PI3K, CDK-5, JnK and MAPK. The splice variant of ApoER2 expressing exon 19 can influence calcium influx in 
response to ligand binding by modulating NMDA receptor-mediated currents via a Src-dependent mechanism. Signaling can 
also be influenced by apoE receptor – APP interaction and specific apoE isoform or Reelin binding.Molecular Neurodegeneration 2006, 1:15 http://www.molecularneurodegeneration.com/content/1/1/15
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binding to APP is a common event for the LDLR family
members and expression and proteolytic processing of
these receptors can impact APP trafficking and processing.
Summary
ApoE receptors are believed to act as a clearance mecha-
nisms for extracellular Aβ and apoE is often associated
with Aβ deposits in post mortem AD brains. The apoE
receptors ApoER2, LRP and LRP1B can directly interact
with and stabilize amyloid precursor causing increased α-
cleavage and reduced Aβ producing cleavage. Thus, apoE
and apoE receptors can influence both levels and produc-
tion of Aβ.
Soluble apoE receptors
In addition to the transmembrane forms of apoE recep-
tors, soluble forms of these receptors have been observed
in vitro and in vivo (Figure 3). Soluble receptors can be gen-
erated by cleavage of transmembrane forms of the recep-
tors (also called "ectodomain shedding"). Extracellular
proteinases responsible for the release of soluble receptors
are commonly metalloproteinases, either membrane
bound (A Disintegrin and Metalloproteinase, ADAMs) or
secreted (Matrix Metalloproteinase, MMPs) [137]. Alter-
nately, soluble receptors can be expressed from alternately
spliced mRNAs that lack a transmembrane domain [138].
Both of these processes are important for regulation of
soluble apoE receptors and functions of membrane
bound apoE receptors.
Soluble LRP
LRP is synthesized as a single polypeptide chain of ~600
kDa and then cleaved in the trans-Golgi network by furin
into a 515-kDa ligand-binding subunit and an 85-kDa
transmembrane subunit that remain non-covalently asso-
ciated with one another as they traffic to the cell surface
[139]. The LRP extracellular region undergoes shedding
from a region close to the membrane by metalloprotein-
ases, releasing a soluble LRP (sLRP) capable of binding
ligands [140,141]. sLRP is detected in human plasma at
nanomolar concentrations [140,141] and in human CSF
[142]. Recent studies have also shown that the cell associ-
ated fragment of LRP can be cleaved at a third, intramem-
branous site by the γ-secretase, releasing its intracellular
domain (ICD) [143,144]. These sequential cleavage
events by furin, metalloproteinases, and γ-secretase
closely resemble those of Notch family proteins [145-
147].
Soluble ApoER2 and VLDLR
Like LRP, ApoER2 and VLDLR undergo extracellular cleav-
ages by metalloproteinases to release soluble receptors as
well as C-terminal, cell-associated fragments, and these
events are induced by Phorbol esters [148]. Furthermore,
the C-terminal fragments are cleaved by γ-secretase [149].
ApoER2 and VLDLR proteolytic events are also increased
by extracellular ligand binding [148]. Interestingly, the
different apoE alleles induced different degrees of release;
both ApoER2 and VLDLR show greatest cleavage follow-
ing apoE2 activation, less with apoE3 and relatively little
with apoE4 [148]. The release of soluble forms of ApoER2
and VLDLR is affected by the presence of splice variants.
ApoER2 and VLDLR both have prominent splice variants
that lack the exon encoding an O-linked glycosylation
site. This region is important in the regulated cleavage of
transmembrane proteins [150]. In addition, some
ApoER2 splice variants contain an exon that encodes a
furin cleavage site in the extracellular domain [59,151].
Furin-dependent cleavage results in extrusion of a soluble
fragment of the receptor [152]. Thus, cleavages of ApoER2
and VLDLR are regulated in part by alternate splicing
events.
Soluble LDLR
Like the other family members, LDLR exists as a soluble
form [153,154]. LDLR shedding from the cell surface is
enhanced by several stimuli, including interferon and
phorbol ester. As for the other apoE receptors, this effect
is dependent upon a cell surface metalloproteinase [154].
Inefficient LDLR exon splicing may also contribute to sol-
uble LDLR isoforms because LDLR ESTs have been
reported which lack (i) exon 12, which causes a frameshift
in the extracellular domain, resulting in a premature ter-
mination codon in exon 13, or (ii) exon 15, which
encodes the LDLR O-linked glycosylation domain
(BG945931 and BQ685399, respectively).
Release of soluble receptors
Numerous transmembrane proteins in addition to the
apoE receptors have soluble forms, including growth fac-
tors and their receptors, cytokine precursors and recep-
tors, cell adhesion molecules, enzymes, and
differentiation factors [155]. To gain insight into the pos-
sible mechanisms of soluble apoE receptors, we will
briefly consider the functions of released extracellular
domains of various other transmembrane proteins.
1. Protein function at a distance from the cell
Certain transmembrane proteins have functions that are
inactive as long as the protein is tethered to the cell sur-
face. Upon cleavage, these proteins become active and
their activities can be carried out at a distance from the
cell. For example, TNF-α is synthesized as a membrane-
bound, inactive protein but is activated by cleavage by the
metalloproteinase TNF-α converting enzyme (TACE)
[156]. Soluble TNF-α can then act as a cytokine in the
maintenance of inflammation. Similarly, transforming
growth factor-α (TGF-α) has a biologically active form on
the cell surface, but its activity is limited to the cell surface.
However, upon surface cleavage, an active TGF-α isMolecular Neurodegeneration 2006, 1:15 http://www.molecularneurodegeneration.com/content/1/1/15
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secreted and acts at a distance [157]. Another example of
membrane bound protein cleavage is APP. Isoforms of
APP containing the Kunitz proteinase inhibitor (KPI)
domain can act as serine proteinase inhibitors at the cell
surface but, once released from the cell surface, act as sol-
uble proteinase inhibitors [158].
2. An initial step in cell signaling
Ligand binding to a cell surface receptor can transduce a
signal inside the cell through several general mechanisms.
One of these involves sequential cleavage of the surface
receptor after ligand binding, releasing extracellular (solu-
ble) and intracellular (membrane-bound) domains. A
subsequent intramembranous (i.e. γ-secretase) cleavage of
the membrane-associated protein then releases the cyto-
plasmic domain for intracellular effects [159]. Thus,
release of the soluble receptor is a required step in the sig-
nal transduction pathway. The large number of proteins
identified as γ-secretase substrates undergo this series of
proteolytic events [160]. One well-studied example of this
mechanism is the Notch receptor [161]. Notch is a recep-
tor for cell surface proteins on adjacent cells (Delta, Jag-
ged, etc.). After ligand binding, Notch undergoes
sequential cleavages to release of its intracellular domain
Soluble apoE receptors Figure 3
Soluble apoE receptors. Processing by γ-secretase cleaves ApoER2, VLDLR, and LRP1 at the membrane. Cleavage by furin 
can release soluble forms of ApoER2 and LRP. In addition, sheddase cleavage can result in soluble forms of all four receptors. 
Soluble ApoER2 fragments from furin or sheddase cleavage contain the ligand-binding regions necessary for interaction with 
Reelin and apoE. These soluble fragments can block endogenous ligand binding to full length receptor acting in a dominant neg-
ative fashion.Molecular Neurodegeneration 2006, 1:15 http://www.molecularneurodegeneration.com/content/1/1/15
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(NICD), which acts as a transcription factor of genes
important to development. No function has been
assigned the soluble fragment of Notch generated by the
initial cleavage. Another example is the proteolysis of
SREBP (sterol responsive element binding protein) at
luminal and intramembranous sites [162]. These cleav-
ages result in the release of the cytoplasmic fragments of
SREBPs that act as transcriptional activators of specific
genes important in cholesterol homeostasis.
3. Inhibition of cell signaling
The soluble form of receptors can bind to soluble ligands
and prevent them from interacting with membrane-
bound receptors, thus preventing their effects on cells.
High affinity receptors for several interleukins (IL-1, IL-4,
IL-15) have shed forms that bind the specific interleukins
and block their actions on cells [163-165]. A soluble ver-
sion of the receptor for advanced glycation end products
(RAGE) can block the interactions of ligands with the
membrane bound forms of RAGE, preventing their endo-
cytosis [166], and a soluble version of the leptin receptor
blocks leptin signaling [167]. Receptor cleavage can also
inhibit signaling that is already occurring on the cell sur-
face. For example, cell surface ephrins interact with Eph
receptors on adjacent cells, promoting both forward and
reverse cell signaling cascades important in development
[168]. The formation of the ligand receptor complex pro-
motes cleavage of the ephrin from the cell surface by
ADAMs, thus ceasing both forward and reverse signaling
events [169].
4. Release of cell adhesion
Transmembrane proteins are vital for establishing stable
connections of a cell with adjacent cells or with the extra-
cellular matrix. When proteolysis of these membrane pro-
teins occurs, the cellular binding to the extracellular
matrix is broken, allowing a cell to migrate, or allowing
portions of a cell to form new interactions. A component
of the cleavage of the ephrin-Eph receptor complex is that
this cleavage allows for the induced axonal repulsion
[170]. Other examples include the cleavage of cell adhe-
sion molecules L1 that disrupts cell-cell adhesion [171],
and cleavage of the discoidan domain receptor 1, that dis-
rupts cell-collagen adhesion [172].
5. Protein turnover
Secreted proteins are often degraded by soluble protein-
ases, or internalized by cells and degraded in endosomes
and lysosomes. Cytoplasmic proteins can be ubiquiti-
nated and degraded by the proteosome [173]. However,
transmembrane proteins cannot be sufficiently degraded
by either of these mechanisms as long as they are mem-
brane bound. Therefore, turnover of transmembrane pro-
teins requires a combination of proteolytic events.
Cleavage at the cell surface would release soluble proteins
for extracellular degradation or clearance. Subsequent
cleavages within the membrane would generate small
protein fragments that could be removed from the mem-
brane, as well as cytoplasmic fragments that could be
degraded by intracellular pathways. The urokinase recep-
tor uPAR undergoes a series of cleavages that may be
responsible for this type of protein turnover[174]. CD44
is another example of a protein that undergoes these
sequential cleavages for degradation [175].
Functions of soluble apoE receptors
These potential functions of soluble receptors each apply
to apoE receptors. One of the most profound implications
of the production of soluble apoE receptors is the possible
dominant negative effect on apoE receptor function. This
action is observed with the production of soluble
ApoER2. The expression of the ApoER2 variant containing
the furin consensus site results in the production of solu-
ble receptor consisting of the ligand binding domain
[152]. Soluble ApoER2 can effectively block Reelin bind-
ing to both ApoER2 and VLDLR and subsequent Reelin-
dependent signaling in primary neuronal cells. Thus, inhi-
bition of normal Reelin signaling through ApoER2 and
VLDLR can acutely modulate other signaling mechanisms
through changes in NMDA receptor activity and intracel-
lular signaling pathways [84-89]. The effect on apoE-
dependent signaling has yet to be determined, but these
studies suggest that selected apoE receptor shedding
would affect both specific ligand binding, as in the case of
soluble ApoER2 and Reelin signaling, as well as overall
apoE binding and signaling.
Other soluble apoE receptors are shown to act in the same
capacity as soluble ApoER2. Soluble LRP can bind RAP in
ligand blots [140] and soluble derivatives of LRP, LDLR,
and VLDLR have each been shown to mediate receptor-
ligand interactions [140,152,176,177]. A physiologic
function has yet to be ascribed to the production of solu-
ble apoE receptors. However, in light of the essential roles
these receptors play in synaptic function, integration into
numerous signal transduction pathways and their wide-
range of their ligands, it is likely that this type of negative
feedback would be necessary in modulating the activity of
specific or multiple apoE receptor subtypes. In addition,
cleavage of apoE receptors could be a necessary step in
receptor turnover, affecting receptor half-lives, and in pre-
venting uptake of apoE-containing lipoproteins. In sum-
mary, release of soluble apoE receptors from the cell
surface may modulate the cell surface apoE receptor path-
way through multiple mechanisms, including ligand
binding away from the cell, altered cell signaling, and dif-
ferences in receptor degradation.Molecular Neurodegeneration 2006, 1:15 http://www.molecularneurodegeneration.com/content/1/1/15
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Summary
Numerous transmembrane receptors undergo proteolytic
processing. Soluble apoE receptors have also been identi-
fied for VLDLR, ApoER2, LDLR and LRP. The specific
physiologic function for apoE receptor processing has yet
to be elucidated. However, a dominant negative effect has
been attributed to the processing of ApoER2 and subse-
quent production of soluble receptor. Thus, specific apoE
receptor shedding may represent a novel mechanism for
modulating individual apoE receptor-ligand interactions
and overall apoE receptor function.
Conclusion
Soluble apoE receptors are generated by two mechanisms,
i.e., proteolysis of transmembrane receptors and by
expression of alternately spliced isoforms of the proteins.
Moreover, splicing also modulates cell surface proteolysis
because exons encoding the O-linked glycosylation
domains of VLDLR, ApoER2 and LDLR are alternatively
spliced, and this glycosylation domain modulates suscep-
tibility to cell surface proteolysis. These soluble receptors
bind their ligands, including apoE, and affect their func-
tion and metabolism. The mechanisms and regulation of
the processes generating soluble apoE receptors, mediat-
ing the actions of these receptors, and controlling the
eventual clearance of the soluble receptors are just now
being examined. Thus, soluble apoE receptors overall may
represent an area of rapid growth in our understanding of
AD-related processes. The importance of receptor shed-
ding as a general regulatory mechanism is being recog-
nized in many fields, with shedding of molecules
important, for example, in development (Notch,
ephrins), immunology (TNF-α, IL-1 receptor, CD44), cell
signaling (SREBP, leptin receptors), and cell adhesion (L1,
discoidan domain receptor 1). Soluble apoE receptors
could play roles as dominant negative regulators of apoE,
and thus understanding their generation and actions are
important for understanding normal apoE functions in
the CNS.
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